Pharmacological approaches to improving cognitive function in Down syndrome: current status and considerations.
about
Timing of therapies for Down syndrome: the sooner, the betterSelf-Organizing Feature Maps Identify Proteins Critical to Learning in a Mouse Model of Down SyndromeSex differences in protein expression in the mouse brain and their perturbations in a model of Down syndrome.Long-term effect of neonatal inhibition of APP gamma-secretase on hippocampal development in the Ts65Dn mouse model of Down syndrome.Deleterious Effects of Chronic Folate Deficiency in the Ts65Dn Mouse Model of Down Syndrome.Protein dynamics associated with failed and rescued learning in the Ts65Dn mouse model of Down syndrome.Maternal Choline Supplementation: A Potential Prenatal Treatment for Down Syndrome and Alzheimer's Disease.Inhibition of APP gamma-secretase restores Sonic Hedgehog signaling and neurogenesis in the Ts65Dn mouse model of Down syndromeAbsence of Prenatal Forebrain Defects in the Dp(16)1Yey/+ Mouse Model of Down Syndrome.An Anti-β-Amyloid Vaccine for Treating Cognitive Deficits in a Mouse Model of Down Syndrome.Cognitive Impairment, Neuroimaging, and Alzheimer Neuropathology in Mouse Models of Down Syndrome.The GABAergic Hypothesis for Cognitive Disabilities in Down SyndromeOverexpressed Down Syndrome Cell Adhesion Molecule (DSCAM) Deregulates P21-Activated Kinase (PAK) Activity in an In Vitro Neuronal Model of Down Syndrome: Consequences on Cell Process Formation and Extension.Mouse models of Down syndrome: gene content and consequences.Outcome Measures for Clinical Trials in Down Syndrome.Aging rather than aneuploidy affects monoamine neurotransmitters in brain regions of Down syndrome mouse modelsTargeting trisomic treatments: optimizing Dyrk1a inhibition to improve Down syndrome deficits.Exome sequencing of Pakistani consanguineous families identifies 30 novel candidate genes for recessive intellectual disability.Epigallocatechin gallate: A useful therapy for cognitive disability in Down syndrome?Aerobic exercise and a BDNF-mimetic therapy rescue learning and memory in a mouse model of Down syndrome.Proteomic analysis of six- and twelve-month hippocampus and cerebellum in a murine Down syndrome model.In vivo and ex vivo analyses of amyloid toxicity in the Tc1 mouse model of Down syndrome.DYRK1A Protein, A Promising Therapeutic Target to Improve Cognitive Deficits in Down Syndrome
P2860
Q26779297-EA6165A2-70F5-44A9-B10B-C5FA4ED09906Q28545764-5C3A6C82-9FEE-44A2-BBE6-4A4AC5813F46Q30398962-A49C73DE-3ED0-4E64-B9CE-919188E39C94Q33711022-FB4FCC4F-1C41-4BF3-9B5B-721E8F322267Q33780762-AD036B5C-7B4C-43BE-8DF8-8CF0B18CE96DQ35202586-C73EF893-2357-461E-BC88-DD7ACD535585Q36522425-7DEC6448-0BE7-4A13-A9D9-AF7CCF417D96Q36621106-6BFBC035-6113-4294-BCE7-5CCA1785729FQ36665885-D865C089-98D9-4122-B1E3-B9EDDA019597Q36739111-516015B0-1D97-4EF0-99C7-F42BAFDC2706Q37279515-46B846FD-019D-47F9-975D-B118A96FD4E3Q37683060-6AFC5CD6-A1FF-4EB7-82FC-CBBB92F2BF30Q38787153-FCC14635-EC28-4F3F-90FB-E8095A46B37BQ38931172-7E63D37F-D028-4E49-8593-5724EF210689Q39269317-66BDFE29-D96D-4997-BAA8-BD693ED373C5Q41184300-29CEBCFB-774C-4CB0-86FD-5213E0E73D82Q41696401-922D29C3-675A-4341-8B2E-33DD6E8F75E3Q42619208-DCD81983-A4F6-40EB-A108-73379E880FDFQ46417261-DB7B89A3-8C28-48B1-80D8-9BA349A7EC3DQ47155189-B43973AC-5F54-4FB7-9D8F-5D95165C8037Q47289623-4AE9ED8A-35AB-49F5-B775-B0E4AF1B6EE8Q47319838-73465623-98B9-49E0-9E0F-7AE64E7CD6D1Q58551676-E031CD96-8547-4D29-9E85-110F5FA57778
P2860
Pharmacological approaches to improving cognitive function in Down syndrome: current status and considerations.
description
2014 nî lūn-bûn
@nan
2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Pharmacological approaches to ...... ent status and considerations.
@ast
Pharmacological approaches to ...... ent status and considerations.
@en
type
label
Pharmacological approaches to ...... ent status and considerations.
@ast
Pharmacological approaches to ...... ent status and considerations.
@en
prefLabel
Pharmacological approaches to ...... ent status and considerations.
@ast
Pharmacological approaches to ...... ent status and considerations.
@en
P2860
P921
P356
P1476
Pharmacological approaches to ...... ent status and considerations.
@en
P2093
Katheleen J Gardiner
P2860
P304
P356
10.2147/DDDT.S51476
P407
P5008
P577
2014-12-17T00:00:00Z